The application of BH3 mimetics in myeloid leukemias
Open Access
- 26 February 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in Cell Death & Disease
- Vol. 12 (2), 1-13
- https://doi.org/10.1038/s41419-021-03500-6
Abstract
Execution of the intrinsic apoptotic pathway is controlled by the BCL-2 proteins at the level of the mitochondrial outer membrane (MOM). This family of proteins consists of prosurvival (e.g., BCL-2, MCL-1) and proapoptotic (e.g., BIM, BAD, HRK) members, the functional balance of which dictates the activation of BAX and BAK. Once activated, BAX/BAK form pores in the MOM, resulting in cytochrome c release from the mitochondrial intermembrane space, leading to apoptosome formation, caspase activation, and cleavage of intracellular targets. This pathway is induced by cellular stress including DNA damage, cytokine and growth factor withdrawal, and chemotherapy/drug treatment. A well-documented defense of leukemia cells is to shift the balance of the BCL-2 family in favor of the prosurvival proteins to protect against such intra- and extracellular stimuli. Small molecule inhibitors targeting the prosurvival proteins, named ‘BH3 mimetics’, have come to the fore in recent years to treat hematological malignancies, both as single agents and in combination with standard-of-care therapies. The most significant example of these is the BCL-2-specific inhibitor venetoclax, given in combination with standard-of-care therapies with great success in AML in clinical trials. As the number and variety of available BH3 mimetics increases, and investigations into applying these novel inhibitors to treat myeloid leukemias continue apace the need to evaluate where we currently stand in this rapidly expanding field is clear.Keywords
Funding Information
- University of Glasgow
- Wellcome Trust (204820/Z/16/Z)
- Novartis
- Bristol-Myers Squibb
- Takeda Pharmaceutical Company
- Cyclacel Pharmaceuticals Inc., Berkeley Heights, New Jersey, United States
This publication has 134 references indexed in Scilit:
- Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemiaGenes & Development, 2012
- Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitorsLeukemia, 2011
- Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemiaJCI Insight, 2010
- Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1Blood, 2010
- FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD–specific STAT5 activationBlood, 2009
- Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009Cell Death & Differentiation, 2008
- Living with death: the evolution of the mitochondrial pathway of apoptosis in animalsCell Death & Differentiation, 2008
- The BCL-2 protein family: opposing activities that mediate cell deathNature Reviews Molecular Cell Biology, 2008
- Bim and Bad mediate imatinib-induced killing of Bcr/Abl + leukemic cells, and resistance due to their loss is overcome by a BH3 mimeticProceedings of the National Academy of Sciences of the United States of America, 2006
- The Hallmarks of CancerCell, 2000